Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
26 participants
OBSERVATIONAL
2011-03-10
2012-12-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. to verify the safety of protein sparing modified fast(PSMF) by enteral route ( EMF )performed in cycles of ten days/months for six months
2. to compare EMF with oral PSMF clinically ( appetite control, fat freemass mantainance, polmonary function tests and metabolic pattern)
3. to verify the weight mantainance after 6 months from the treatment suspension
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. to verify the safety of protein sparing modified fast by enteral route ( EMF )in cycles of ten days/months repeated for six months,
2. To compare EMF with oral PSMF clinically ( appetite control, polmonary function tests and metabolic pattern) and on metabolic parameters (hypertension, glucose intolerance, dyslipidaemia) maintaining body composition (particularly fat free mass and muscular strength) in 15 patients with disease-causing obesity not responding to medical treatment and/or cognitive/behavioural therapy, who are candidates for invasive treatment such as the gastric balloon or surgery but do not intend to undergo them compared with 15 undergoing the same regimen without the naso-gastric tube. To verify the effects of treatment with regard to the enteral-hormonal structure during the acute phase (selected sub-group) and while undergoing treatment.
B) Secondary endpoints:
1. To verify the percentage of patients who maintain the weight reached 6 months after stopping treatment with the naso-gastric tube associated with a high-calorie normal-protein diet.
2. Verify clinical safety of EN in these patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
'enteral protein tube feeding in obese
protein sparing modified fast with a defined enteral formula by tube
enteral protein tube feeding in obese
The intervention is represented by a new alternative to treat obese patients by means of a protein sparing modified fast administered by continous 24 h enteral feeding
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
enteral protein tube feeding in obese
The intervention is represented by a new alternative to treat obese patients by means of a protein sparing modified fast administered by continous 24 h enteral feeding
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* aged between 16 and 75
* with BMI 30 - 45 Kg/m2
* that are not in a restricted diet since at least 3 months
* with obesity related comorbidities (- type 2 diabetes
* mild or moderate OSAS
* orthopedic diseases (coxarthrosis, gonarthrosis)
* hypertension
* non alcoholic hepatic steatosis
* accepting to be enrolled in the study (signing informed consent)
Exclusion Criteria
* Presence of cancer
* Patients treated with gastrolesive or anticoagulant drugs
* Hepatic failure, renal failure or multi-organ failure (cut off)
* Contraindications for enteral nutrition,Mechanical bowel complete, or partial chronic obstruction
* Severe mesenteric ischemia not caused by hypovolemia
* Digiunal or ileal fistula with high output (400 mL/die)
* Severe modifications of the intestinal function caused by enteropathies or insufficient absorbent surface, to the point that a normal nutritional state cannot be maintained
* Type 1 diabetes
* Type 2 diabetes treated with oral or injected drugs that may cause hypoglycemia
* ANBN: anorexia or bulimia nervosa, evaluation of other symptoms by specific tests
* Patients with major psychiatric disorders or not cooperative, or with alcohol or drug addiction disorders.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nestlé Foundation
OTHER
M.D. Samir G. Sukkar
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
M.D. Samir G. Sukkar
Chief Clinical Nutrition Unit
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Samir G Sukkar, MD
Role: STUDY_DIRECTOR
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Genova, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EMF2011
Identifier Type: -
Identifier Source: org_study_id